TABLE 3.
Results of anti-MIP-2 MAB studya
| Anti-MIP-2 MAB treatment | Day | % of mononuclear cell subset (n = 4)
|
Virus titer (PFU/mg of tissue) (n) | BW (g) (n = 7) | HW/BW ratio (103) (n = 7) | |||
|---|---|---|---|---|---|---|---|---|
| Mφ | Pan T | CD4 | CD8 | |||||
| Group 1 (none) | 2 | (4.6 ± 2.5) × 105 (4) | ||||||
| 4 | (4.6 ± 1.8) × 106 (4) | |||||||
| 7 | 6.5 ± 2.4 | 16.5 ± 3.1 | 9.5 ± 2.1 | 7.3 ± 1.0 | (3.3 ± 2.7) × 103 (7) | 20.8 ± 1.7 | 7.2 ± 0.6 | |
| 14 | 14.0 ± 3.9 | 24.3 ± 4.4 | 17.8 ± 2.5 | 13.0 ± 2.5 | NDb (3) | 25.5 ± 1.5 | 7.7 ± 0.5 | |
| Group 2 (10 μg/day) | 2 | (3.6 ± 2.9) × 105 (4) | ||||||
| 4 | (3.8 ± 2.9) × 106 (4) | |||||||
| 7 | 4.0 ± 1.4 | 15.0 ± 2.2 | 9.5 ± 1.9 | 6.3 ± 1.7 | (4.5 ± 3.2) × 103 (7) | 20.8 ± 1.1 | 7.2 ± 0.7 | |
| 14 | 8.8 ± 1.5 | 21.0 ± 3.2 | 16.3 ± 1.9 | 12.8 ± 5.6 | ND (3) | 24.5 ± 1.1 | 7.5 ± 0.6 | |
| Group 3 (100 μg/day) | 2 | (4.7 ± 1.6) × 105 (4) | ||||||
| 4 | (3.9 ± 1.5) × 106 (4) | |||||||
| 7 | 3.0 ± 0.8* | 9.0 ± 1.8** | 5.3 ± 1.3* | 3.0 ± 0.8** | (2.9 ± 2.6) × 103 (7) | 20.8 ± 1.9 | 6.4 ± 0.7 | |
| 14 | 6.8 ± 2.1* | 14.8 ± 3.2* | 9.8 ± 1.3** | 7.0 ± 2.5* | ND (3) | 25.3 ± 1.0 | 6.7 ± 0.6** | |
a
Mice were injected subcutaneously with anti-MIP-2 MAb at 10 μg/day (group 2) and at 100 μg/day (group 3) on days 0 to 5. Subsets of mice were killed on days 7 and 14. The BW and HW/BW ratio were calculated. The percentages of positively stained mononuclear cells were calculated as previously described (16, 17). Myocardial virus titers were determined by a plaque assay. Values are means ± standard deviations. ∗ and ∗∗, P < 0.05 and P < 0.01, respectively, versus control.
b
ND, not detected.